The United Bio-technology (hengqin) Co., Ltd.

This study tested a new once-weekly injection called UBT251 in 211 adults with type 2 diabetes. Participants received either UBT251, a placebo, or the existing drug semaglutide for 24 weeks. The main goal was to see how well UBT251 lowers blood sugar (HbA1c) and to find the right…

This study tested a new weekly injection called UBT251 in 205 overweight or obese adults to see if it helps with weight loss. Participants received different doses of the drug or a placebo for 24 weeks. The main goal was to measure the percentage change in body weight, with addit…